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Background: Whether serum triglyceride level correlates with clinical outcomes of patients with ST segment elevation
myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI) remains unclear.
Methods: From June 2008 to February 2012, all patients with STEMI who were treated with pPCI in this tertiary
referral hospital and then had fasting lipid profiles measured within 24 hours were included and dichotomized into
lower- (≦150 mg/dl) and higher-triglyceridemic (>150 mg/dl) groups. Baseline characteristics, in-hospital outcomes, and
late major adverse cardiovascular events (MACE) were compared in-between. Independent predictors for in-hospital
death and late adverse events were identified by multivariate logistic and Cox regression analyses.
Results: A total of 247 patients were enrolled, including 163 lower-triglyceridemic and 84 higher-triglyceridemic
subjects. The angiographic characteristics, pPCI results and in-hospital outcomes were similar between the two
groups. However, multivariate logistic analysis identified triglyceride level as a negative predictor for in-hospital death
(OR 0.963, 95% CI 0.931-0.995, p = 0.023). At follow-up for a mean period of 1.23 to 1.40 years, compared with the
high-triglyceridemic group, low-triglyceridemic patients had fewer cumulative incidences of target vessel
revascularization (TVR) (21.7% vs. 9.5%, p = 0.011) and overall MACE (26.1% vs. 11.9%, p = 0.0137). Cox regression
analysis confirmed serum triglyceride as a negative predictor for TVR and overall MACE.
Conclusions: Serum triglyceride level inversely correlates with in-hospital death and late outcomes in patients with
STEMI treated with pPCI. Thus, when managing such patients, a high serum triglyceride level can be regarded as a
benign factor but not a target for aggressive therapy.
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Atherosclerotic cardiovascular disease remains the lead-
ing cause of disability and death in the Western world
[1]. When coronary arteries are involved, ST-segment
elevation myocardial infarction (STEMI) manifests an
extreme presentation that carries ominous short- and
long-term prognosis in terms of fatal arrhythmia, acute
pumping failure, myocardial rupture and chronic left
ventricular dysfunction [2]. Timely primary percutan-
eous coronary revascularization (pPCI) is well estab-
lished as the most effective therapy for restoring vessel
patency, salvaging jeopardized myocardium and preserv-
ing cardiac performance [2,3]. However, a substantial
proportion of patients are still at risk of early electrical/
mechanical complications and late major adverse cardiac
events (MACE) from myocardial stunning, unfavorable
left ventricular remodeling, culprit lesion restenosis and
de novo coronary stenosis [4], raising identification of
high-risk patient subsets as an essential issue in the goal
to improve the overall outcome of such a disease.
The chief prognostic determiners for patients with
STEMI are the sizes of the infarcted and residual viable
myocardium. When the culprit vessel is successfully
opened by pPCI and the ischemic territory is thereby
limited, a number of other factors may play a predictive
role in determining the prognosis of these patients.
Among such factors low-density lipoprotein (LDL) is
closely related with early and late cardiovascular events
[5] in patients with acute coronary syndrome; hence the
use of aggressive statin therapy for these patients is justi-
fied to benefit cardiovascular outcome [6]. In contrast,
whether serum triglyceride (TG) correlates with the out-
come of STEMI and how it should be managed remains
unclear. Some investigations showed that hypertriglyc-
eridemia independently predicted development of coron-
ary artery disease (CAD) [7,8] and myocardial infarction
[9] as hypercholesterolemia did [10], whereas others re-
ported low TG levels were associated with poorer prog-
nosis in some cardiac and non-cardiac disease states
[11-13]. Given the controversial yet potentially crucial
impact of hypertriglyceridemia on the outcome of pa-
tients with STEMI treated by pPCI, this study was
designed to elucidate the differences in short- and long-
term cardiovascular outcomes between patients with
high- and low-serum TG levels. The results of this study
could clarify the role of serum TG in determining the
prognosis of patients suffering from STEMI, and may
help guide proper management of such patients to im-
prove their overall outcome.
Methods
Patients
From June 2008 to February 2012, of the 301 patients
admitted to this tertiary referral center with a diagnosisof STEMI for primary PCI (pPCI), 247 had a lipid profile
checked within 24 hours of admission so were enrolled
and categorized into either the lower (≦150 mg/dl,
N = 163, or 66%) or the higher (>150 mg/dl, N = 84, or
34%) triglyceride group according to the baseline level of
serum triglycerides. Baseline characteristics, angio-
graphic findings, and clinical outcomes were obtained
from electronic or written medical records as well as the
cardiac catheterization laboratory database and were
compared between groups. The study protocol was ap-
proved by the human research committee of Taichung
Veterans General Hospital (approval No. CE12289), and
requirement of informed consent was waived by the in-
stitutional review board.
Coronary angiography and percutaneous coronary
intervention
The diagnosis of STEMI was made based on conven-
tionally standardized criteria [2]. Coronary angiography
was performed from either a radial or femoral approach
at the discretion of the interventional cardiologists.
Grade of blood flow was determined by TIMI classifica-
tion system [14]. Angiographic stenosis was defined as a
luminal diameter reduction of ≥50% by quantitative cor-
onary angiography, and critical stenosis was defined as
≥70% narrowing of the coronary artery luminal diameter.
Complete coronary occlusion was defined as absence of
antegrade flow of contrast media beyond a specific vas-
cular segment. The infarct-related lesion was determined
by the relevant ECG leads showing ST-segment elevation
(or ST-segment depression along with a tall R wave in
lead V1 for posterior infarction) and by the typical vas-
cular morphological features of thrombus-laden or hazy
filling defects along with compromise of distal flow.
Once angiographic occlusion or critical stenosis of any
of the coronary arteries was demonstrated, PCI with or
without stenting was performed for the infarct-related
artery but not for any other bystander vessel unless
hemodynamic instability persisted despite opening of
the culprit lesion. The success of pPCI was defined as
achievement of the TIMI flow of the infarct related ar-
tery to grade II or III. Patients were then taken to our
intensive coronary care unit for post-procedural care.
Pharmacological treatment, including dual-antiplatelet
medication, was in accordance with current guidelines
[2]. In-hospital complications, including cardiogenic shock
requiring intra-aortic balloon pumping support, new-
onset atrial fibrillation, ventricular arrhythmia, and death
served as in-hospital outcomes.
Follow-up
Discharged patients were followed up by medical records
of clinic visits or telephone contacts for MACE, includ-
ing data regarding non-fatal myocardial infarction, target
Table 1 Baseline characteristics of patients in the







Age, yrs 67.1 ± 13.2 56.1 ± 11.3 <0.001
Female (%) 22 (13.6) 19 (22.6) 0.100
Hypertension (%) 97 (59.5) 61 (72.6) 0.058
DM (%) 46 (28.2) 34 (40.5) 0.071
Smoking (%) 99 (60.7) 56 (66.7) 0.439
BMI, kg/m2 24.1 ± 3.5 26.3 ± 3.2 <0.001
Previous CAD (%) 22 (13.5) 5 (6.0) 0.113
Previous stroke (%) 15 (9.2) 5 (6.0) 0.522
Carotid stenosis (%) 4 (2.5) 0 (0) 0.303
PAD (%) 3 (1.8) 2 (2.4) 1.000
eGFR, ml/min 46.7 ± 18.5 57.6 ± 20.5 <0.001
Previous hypolipid drugs
Statin 21 (12.9) 12 (14.3) 0.913
Fibrate 1 (0.6) 3 (3.6) 0.115
Admission lipid profile
HDL, mg/dl 45.4 ± 10.8 37.4 ± 8 <0.001
LDL, mg/dl 100.9 ± 31.6 106.6 ± 41.4 0.231
TC/HDL 3.65 ± 0.87 5.02 ± 1.36 <0.001
LDL/HDL 2.32 ± 0.81 2.93 ± 1.28 <0.001





Cardiogenic shock (%) 29 (17.8) 7 (8.3) 0.071
BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus;
eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL,
low-density protein; PAD, peripheral arterial disease; TC, total cholesterol;
TG, triglyceride.
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bypass grafting, cardiac death and all-cause mortality.
Use of lipid-lowering agents (chiefly statins and fibrates)
and non–lipid-lowering drugs (aspirin, clopidogrel, cilos-
tazol, β-blockers, angiotensin-converting enzyme inhibi-
tors, angiotensin receptor antagonists, aldactone receptor
blockers) was compared between groups.
Statistical analysis
Continuous variables were expressed as mean ± standard
deviation (SD). Normally distributed continuous data were
compared between groups by unpaired student’s T-test,
while non-parametric continuous data were compared by
Mann–Whitney U test. Categorical variables were com-
pared by χ2 analysis with Fisher’s exact correction. Univar-
iate followed by multivariate logistic regression analyses
were used to identify independent correlates of in-hospital
mortality in all patients. Rationale variables selected for re-
gression analysis included the following: demographic
characteristics, co-morbid illnesses, echocardiographic in-
dicators, and angiographic features. Variables were tested
in a backward conditioned multivariate logistic regression
model if their univariate P values were <0.20. Statistical
significance was defined as a multivariate P <0.05. The
odds ratios and their 95% confidence intervals (CIs) from
the multivariate logistic regression analysis were used as
estimates of relative risk. Kaplan-Meier survival curves for
components of MACE and overall MACE rate were con-
structed and compared between groups with the Log-
Rank test. Multivariate Cox proportional hazard analysis
was used to determine the independent predictors of TVR
and overall MACE after adjustment for baseline and
angiographic variables with unequal distribution. A p-
value <0.05 was considered significant for all analyses.
Statistical analysis was done using SPSS 11.5 or SAS 9.3.
Results
Patient characteristics
The demographic data of both groups of patients are
listed in Table 1. Patients in the lower-TG group were
older (67 vs. 56 years, p < 0.01) and had lower body mass
index, worse estimated glomerular filtration rate, higher
high-density lipoprotein (HDL) as well as lower total
cholesterol levels than those in the higher-TG group.
ECG, coronary angiographic findings, pPCI results and
in-hospital outcomes
The territory of myocardial infarction determined by ECG
was mostly located in the anterior wall in both groups
(Table 2). The severity of overall coronary artery disease,
the culprit lesion vessel, the ECG-to-balloon time and the
therapeutic modalities of pPCI in terms of balloon angio-
plasty, thrombectomy, and endovascular stenting were
similar between the two groups (p =NS in all). Successof PCI (post-procedural TIMI-blood flow to ≧grade 2)
was accomplished in most of the patients in both groups
(p =NS). Though post-procedural left ventricular ejection
fraction estimated with either ventriculography or echocar-
diography was more depressed in the low-TG group (44.8%
vs. 46.9%, p = 0.031), myocardial infarct size estimated
by peak creatinine kinase (CK) levels was comparable be-
tween the two groups. Occurrence of new cardiogenic
shock, respiratory failure, atrial fibrillation and ventricular
arrhythmia, as well as requirement of emergency coronary
bypass surgery was also statistically equivalent in the two
groups (p =NS in all). Though in-hospital mortality hap-
pened in 6 patients in the lower TG (5 from ventricular
arrhythmia and 1 from refractory pumping failure) but 0 in
the higher TG group, the difference was not statistically sig-
nificant (p = 0.098). Further univariate followed by multi-
variate regression analysis identified peak CK and CAD
number >1 as positive, whereas serum TG level as negative
predictors of in-hospital death for all of these patients
(Table 3).
Table 2 ECG location of STEMI, findings of coronary
angiograms and results of primary percutaneous








Anterior (%) 87 (53.4) 51 (60.7) 0.334
Inferior (%) 72 (44.2) 33 (39.3) 0.548
True posterior (%) 2 (1.2) 2 (2.4) 0.607




1.8 ± 0.8 1.8 ± 0.8 0.906
SVD (%) 76 (46.6) 37 (44.0) 0.802
DVD (%) 50 (30.7) 30 (35.7) 0.501
TVD (%) 37 (22.7) 17 (20.2) 0.779
LM involvement (%) 7 (4.3) 1 (1.2) 0.271
Treated (culprit) vessel
LM (%) 2 (1.2) 1 (1.2) 1.000
LAD (%) 86 (52.8) 51 (60.7) 0.291
LCx (%) 18 (11) 6 (7.1) 0.451
RCA (%) 57 (35) 28 (33.3) 0.908
Ramus medianus (%) 1 (0.6) 0 (0) 1.000
Door to balloon time, min 90.5 ± 42.1 87.7 ± 29 0.587
Interventions
Balloon angioplasty (%) 161 (98.8) 81 (96.4) 0.341
Thrombectomy
Aspiration (%) 103 (63.2) 55 (65.5) 0.83
Rheolytic (%) 3 (1.8) 2 (2.4) 1.000
Stenting
Nil (%) 15 (9.2) 10 (11.9) 0.657
DES (%) 37 (22.7) 21 (25.0) 0.806
BMS (%) 108 (66.3) 52 (61.9) 0.591
DES + BMS (%) 3 (1.8) 1 (1.2) 1.000
Final TIMI flow
Grade 3 (%) 153 (93.9) 82 (97.6) 0.231
Grade 2 (%) 10 (6.1) 2 (2.4) 0.231
Grade 1/0 (%) 0 (0) 0 (0) 0
In-hospital outcome
LVEF, % 43.8 ± 10.9 46.9 ± 9.5 0.031
Cardiac markers






New cardiogenic shock (%) 21 (12.9) 6 (7.1) 0.248
Respiratory failure (%) 30 (18.4) 8 (9.5) 0.100
Ventricular arrhythmia (%) 25 (15.3) 8 (9.5) 0.282
Table 2 ECG location of STEMI, findings of coronary
angiograms and results of primary percutaneous
coronary interventions in all patients (Continued)
New atrial fibrillation (%) 16 (9.8) 3 (3.6) 0.142
Emergency CABG (%) 0 (0) 2 (2.4) 0.115
In hospital Death* (%) 6 (3.7) 0 (0) 0.098
*All were related with refractory heart failure, with 5 of them experiencing
ventricular arrhythmia before death. BMS, bare-metal stent; CABG, coronary
artery bypass grafting surgery; CAD, coronary artery disease; CK, creatinine
kinase; DES, drug-eluting stent; DVD, double vessel disease; LAD, left anterior
descending artery; LCx, left circumflex artery; LM, left main coronary artery;
RCA, right coronary artery; SVD, single vessel disease; TIMI, thrombolysis in
myocardial infarction; TVD, triple vessel disease.
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The medications prescribed at discharge were similar in
the two groups of patients surviving the STEMI epi-
sodes, except that fibrates were given more often in
higher-TG patients with the intention to lower serumTable 3 Independent predictors of in-hospital mortality
in patients with STEMI undergoing pPCI
Variable Hazard
ratio
95% C.I. P* P†
Variables in the model
CAD number 4.620 1.006-21.223 0.038 0.049
1 (reference) 1
>1 4.620 1.006-21.223 0.038 0.049
Peak CK 1.001 1.000-1.001 0.001 0.003
TG 0.963 0.931-0.995 0.049 0.023






ECG to balloon time 0.753
LM involvement 0.102 NS





Culprit LM 0.015 NS




*From univariate regression analysis, †from multivariate regression analysis.
CAD, coronary artery disease; CK, creatinine kinase; DM, diabetes mellitus; LAD,
left anterior descending artery; LCx, left circumflex artery; LM, left main
coronary artery; RCA, right coronary artery; TIMI, thrombolysis in myocardial
infarction; TG, triglyceride.
Table 5 Independent predictors of TVR and overall MACE
by multivariate Cox regression analysis in all patients
Variable Hazard ratio 95% C.I. P
TVR
TG* 0.993 0.988-0.998 0.007
CAD number*
1 (reference) 1
>1 2.717 1.655-4.458 <0.001
Overall MACE
TG* 0.994 0.990-0.999 0.016
CAD number*
1 (reference) 1
>1 2.706 1.730-4.234 <0.001
*Adjusted for age, gender, smoking, diabetes mellitus, left ventricular ejection
fraction, peak creatinine kinase level, balloon angioplasty only, bare-metal
stent, drug-eluting stent, low-density lipoprotein level, all medications and
high-density lipoprotein level. CAD, coronary artery disease; MACE, major adverse
cardiovascular event; TG, triglyceride; TVR, target vessel revascularization.
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that during a mean follow-up period of 1.23 years
for lower-TG and 1.4 years for higher-TG patients
(p = 0.126), lower-TG patients had significantly more in-
cidences of TVR (21.7% vs. 9.5%, Log-Rank p = 0.0111)
and in turn overall MACE (26.1% vs. 11.9%, Log-Rank
p = 0.0137) compared to higher-TG patients, yet the
rates of de novo lesions, non-fatal MI, cardiac deaths
and all-cause mortality were comparable between groups
(Table 4). Multivariate Cox proportional hazard model
confirmed that, besides the number of diseased coronary
arteries as a positive predictor, serum TG level inversely
correlated with TVR (hazard ratio 0.993, 95% CI 0.988-
0.998, p = 0.007) and overall MACE (hazard ratio 0.994,
95% CI 0.990-0.999, p = 0.016) in all of our study pa-
tients (Table 5).
Discussion
Patients with coronary artery disease presenting as
STEMI might develop early fatal/non-fatal complications
and late MACE in terms of target lesion revasculariza-
tion, non-fatal myocardial infarction and cardiac death
despite being successfully treated by pPCI. This study,
which investigated the possible relations between serum
TG and in-hospital as well as late outcomes of such pa-
tients, indicated that serum TG level correlates nega-









Aspirin (%) 153 (97.5) 84 (100.0) 0.301
Clopidogrel (%) 154 (98.1) 83 (98.8) 1.000
*RAAS inhibitor (%) 145 (92.4) 77 (91.7) 1.000
Beta Blocker (%) 77 (47.2) 47 (56.0) 0.375
Statin (%) 91 (58) 54 (64.3) 0.414
Fibrate (%) 2 (1.3) 11 (13.1) <0.001
Follow-up years (mean) 1.23 (0.22-3.78) 1.40 (0.44-3.73) 0.126
MACE
Non-fatal MI (%) 17 (10.8) 3 (3.6) 0.0731†
TVR (%) 34 (21.7) 8 (9.5) 0.0111†
De novo lesion (%) 9 (5.7) 4(4.8) 0.404†
Cardiac Death (%) 7 (4.5) 0 (0) 0.1688†
All-Cause Mortality (%) 13 (8.3) 1 (1.2) 0.1392†
Overall (%) 41 (26.1) 10 (11.9) 0.0137†
*Including angiotensin-converting-enzyme inhibitors and angiotensin-II receptor
blockers. †derived from Log-Rank test. MACE, major adverse cardiovascular events;
MI, myocardial infarction; RAAS, rennin-angiotensin-aldosterone system; TVR,
target vessel revascularization.dl predicts fewer incidences of late TVR and in turn
overall MACE. These findings illustrate the paradoxically
inverse relation between serum TG level and clinical
outcome of patients with STEMI treated with pPCI, and
may justify exclusion of specific TG-lowering therapy
from the standard therapeutic regimen in management
of such patients in the long term.
Role of TG in in-hospital outcome of STEMI
The role of serum TG in the pathogenesis of CAD is not
as clear as that of serum LDL. A number of clinical
studies reported a positive association between TG level
and severity of CAD [7,15-17], whereas others demon-
strated conflicting results [18-20]. Investigations involv-
ing histological research found that triglycerides played a
constitutive role in atherosclerotic plaques yet were
rarely identified in active coronary artery lesions as a
culprit component [21]. These findings suggest that tri-
glycerides might be merely an innocent bystander rather
than a direct atherogenic mediator [22-24], and this con-
cept may offer some explanation for our findings that
patients with higher TG levels are not at risk of poorer
in-hospital outcome after STEMI. In fact, our results
demonstrate that there exists a paradoxical trend toward
more in-hospital deaths in patients with lower TG levels,
though the between-group difference did not reach stat-
istical significance possibly due to limited patient num-
ber and confounding by coexistent variables. The role
that serum TG plays as an independent negative pre-
dictor for in-hospital deaths, finally shown by multivari-
ate regression analysis in this study, has similarly been
reported in patients with acute stroke [11-13] and acute
coronary syndrome [25], but is not easy to understand
compared to the roles played by CK level and CAD
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represent surrogates of infarct size and ischemic myo-
cardial territory thus are rationally related with in-
hospital mortality. One possible explanation for the
inverse relation between TG level and in-hospital mor-
tality comes from the findings that incidences of new
atrial arrhythmia, ventricular arrhythmia, respiratory fail-
ure and new cardiogenic shock all tended to be higher in
the lower TG group, along with the exclusive occurrence
of lethal ventricular arrhythmia and refractory heart failure
in 6 (3.7%) of lower TG patients but not in any of higher
TG group. These results implicate the potential role of
serum TG in stabilizing the infarcted, stunned or reper-
fused myocardium after an acute STEMI episode. Another
possibility may be based on the concept that serum TG
level is an indicator of nutritional status. Lower TG levels
denote poorer nutritional condition which could halt myo-
cardial and whole body recovery from STEMI, in turn
subjecting patients to in-hospital deaths. This hypothesis
gains support from some epidemiologic studies describing
low body mass index and serum cholesterol level as
markers of poor health status in older subjects [26-28],
and from clinical investigations reporting worse outcome
in patients with advanced heart failure or various cardio-
vascular diseases and low serum cholesterol [29,30] or TG
concentrations [11-13]. Further studies are needed to de-
termine the exact pathophysiological relations between
serum TG level and in-hospital outcome in patients with
STEMI who receive pPCI treatment.
Role of TG in late outcome of STEMI
Previous studies have demonstrated that even after pri-
mary PCI a considerable proportion of patients with
STEMI still succumb to subsequent MACE due to left
ventricular remodeling and coronary restenosis [31]. The
distinct pathogenesis of restenosis caused by smooth
muscle cell proliferation rather than lipid-related neo-
atherosclerosis [32] explains the poor preventive efficacy
of lipid-lowering medications, particularly statins, on
inhibition of neointimal formation in this entity of
lesions [33-35]. Nonetheless, whether higher TG-rich
lipoprotein is [36,37] or is not [34] related with the rest-
enotic phenomenon remains debatable. The current
study demonstrated that risk of de novo atherosclerosis
was similar between groups with higher or lower TG
levels but overall MACE rates, contributed mostly from
incidence of TVR, were significantly lower in high-TG
patients. These results suggest a potential action of
serum TG against neointimal proliferation at the
STEMI-related lesion sites ever treated by angioplasty
or stenting. This phenomenon has ever been reported
in an in vitro study describing the distinct effects
of various TG particles on either stimulation or sup-
pression of the proliferative activity of vascular smoothmuscle cells [38]. Our findings further indicate that
though hypertriglyceridemia is regarded as an inde-
pendent risk factor for atherosclerosis [39] when coex-
istent with low HDL- and elevated LDL-cholesterol and
needs to be treated after the LDL goal is reached [25],
application of such a therapeutic strategy to patients
with STEMI post-pPCI is not warranted. On the contrary,
the paradoxically inverse relation between hypertriglyc-
eridemia and better late outcome in patients with STEMI
treated with pPCI may justify exclusion of specific TG-
lowering therapy from the standard therapy in long-term
management of such patients. Whether there exists a
“J-curve relationship” between serum TG level and the
outcome of patients with STEMI treated with pPCI awaits
further clarification.Conclusion
On-admission serum TG levels inversely correlate with
in-hospital deaths of patients with STEMI treated with
pPCI, and those with TG levels below 150 mg/dl have a
worse long-term outcome in terms of TVR and overall
MACE than those with higher levels. Thus, serum TG
can be regarded as a mediator that protects such pa-
tients from short and late cardiovascular events rather
than a hazard factor, and hence does not warrant aggres-
sive pharmacological treatment to lower it to the so-
called normal level.
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